by Dom Partridge | Mar 31, 2026 | Uncategorised
Written by Ben Clark, Paloma Charlesworth, and Kiera Lander This quarterly update highlights recent and upcoming developments shaping the health technology assessment (HTA) environment across Europe, with a particular focus on rare diseases, EU‑level...
by Dom Partridge | Feb 27, 2026 | Uncategorised
Written by Jo Wallis, Head of Commercialisation and Pricing Strategy The recent developments put forward by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Food and Drug Administration (FDA) to streamline the regulatory approval processes...
by Dom Partridge | Feb 26, 2026 | Uncategorised
Written by Emma Bartram, Associate Systematic Review Analyst A rare disease is one that affects fewer than 1 in 2,000 individuals, and yet 3.5–5.9% of people will experience a rare disease over the course of their lifetime (1,2). Many of these rare conditions...
by Dom Partridge | Dec 9, 2025 | Uncategorised
By Toby Hobbs Changes to NICE ICER thresholds confirmed NICE has announced that from April 2026 there will be an increase to its cost-effectiveness threshold. This marks one of the biggest shifts in UK Health technology assessment (HTA) practice in years and...
by acaballero | Nov 18, 2025 | Uncategorised
Written by Paloma Charlesworth (Assistant Project Manager) Background Health inequalities are systematic, avoidable, and unjust differences in health outcomes between patient groups. Despite decades of policy and research, they not only persist but in some...
by Dom Partridge | Oct 31, 2025 | Uncategorised
By Kiera Lander October brought real movement across the health technology assessment (HTA) landscape — not just in HealthTech, but across medicines, strategy, and international collaboration. From National Institute for Health and Care Excellence (NICE)...
